TITLE

Once-daily PAH drug OK'd

PUB. DATE
July 2007
SOURCE
Drug Topics;7/9/2007, Vol. 151 Issue 13, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article provides information regarding Ambrisentan in 5- and 10-mg tablets which has been approved by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension. Gilead Sciences developed and tested the drug in two phase III clinical trials involving 393 patients. The new drug must be accessed through the Letairis Education and Access Program due to its potential to cause liver injury and birth defects. Only pharmacies and prescribers registered with LEAP are able to prescribe and distribute Ambrisentan.
ACCESSION #
25886308

 

Related Articles

  • New PAH drug improves exercise capacity. Belden, Heidi // Drug Topics;7/23/2007, Vol. 151 Issue 14, p44 

    The article reports on the U.S. Food and Drug Administration's approval of once-daily oral tablet ambrisentan from Gilead Sciences Inc. for the treatment of pulmonary arterial hypertension with World Health Organization Functional Class II or III symptoms. The drug is an endothelin receptor...

  • New drug approved for pulmonary arterial hypertension. Young, Donna // American Journal of Health-System Pharmacy;8/1/2007, Vol. 64 Issue 15, p1562 

    The article reports on the marketing approval given by the U.S. Food and Drug Authority (FDA) to Gilead Science Inc.'s ambrisentan or Letairis, an endothelin-receptor antagonist for the treatment of pulmonary arterial hypertension. The drug's approval, which was strongly regulated due to the...

  • 2 Companies Stumble Over PAH; Therapies Prove Difficult. Winter, Peter // BioWorld Insight;8/27/2012, Vol. 20 Issue 35, p3 

    No abstract available.

  • Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials.  // Current Medical Literature: Pulmonary Hypertension;2012, Vol. 3 Issue 4, p129 

    The article focuses on a study which explores the potential of change in 6-minute walk distance (6MWD) to predict clinical outcome of pulmonary arterial hypertension (PAH). It notes the association of an absolute change in 6MWD of just over 40 meters with 95 percent certainty of an improved...

  • FDA Wants More Data for Gilead's CF Infection Drug. Young, Donna // BioWorld Today;9/18/2008, Vol. 19 Issue 182, p1 

    The article reports on the request by the U.S. Food and Drug Administration (FDA) for an additional clinical study before it considers approving Gilead Sciences Incorporated's inhaled version of aztreonam lysine to treat cystic fibrosis-related pseudomonal infections. Gilead said that the FDA in...

  • EMEA and FDA Team Up on GCP. O'^Donnell, Peter // Applied Clinical Trials;Sep2009, Vol. 18 Issue 9, p24 

    The article focuses on the partnership between the European Medicines Agency (EMEA) and the U.S. Food and Drug Administration (FDA) to launch joint initiative to collaborate on international Good Clinical Practice (GCP) inspection activities. It mentions that EMEA and FDA will share information...

  • Driving Clinical Trial Innovation. Xiao-Wei Zhu // Applied Clinical Trials;Sep2005, Vol. 14 Issue 9, p66 

    Discusses the potential of the U.S. Food and Drug Administration's Critical Path Initiative to drive clinical trial innovation in the United States. Slowdown in the rate of promising medications and treatments actually reaching patients; Initiative's encouragement of cooperation between...

  • A Declaration of Action. Rucker, David; Parno, Jeff // Applied Clinical Trials;Sep2005, Vol. 14 Issue 9, p62 

    Considers the implications of the U.S. Food and Drug Administration's (FDA) Critical Path Initiative for medical products development for the clinical research industry in the United States. Findings of the March 2004 FDA report "Challenge and Opportunity on the Critical Path to New Medical...

  • …and I'll Take the Low Road. Clinton, Patrick // Pharmaceutical Executive;Jul2004, Vol. 24 Issue 7, p14 

    Focuses on the debate over the creation of a registry of clinical trial results. Perception of some people that a clinical trials registry is a simple matter of good science; Improvement in access to clinical studies; View that the Food and Drugs Administration should be the lone decision-maker...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics